Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: Results from International Breast Cancer Study Group Trial V

Cancer

Volumn 97, Issue 7, 2003, Pages 1591-1600

  Spataro, Vito J ^a,b   Litman, Heather ^c,d   Viale, Giuseppe ^e   Maffini, Fausto ^e   Masullo, Michele ^e   Golouh, Rastko ^f   Martinez Tello, Francisco J ^g   Grigolato, Piergioranni ^h,i   Shilkin, Keith B ^j   Gusterson, Barry A ^k,l   Castiglione Gertsch, Monica ^m   Price, Karen ^c,n   Lindtner, Jurii ^f   Cortés Funes, Hernan ^g   Simoncini, Edda ^o   Byrne, Michael J ^p   Collins, John ^q   Gelber, Richard D ^c,d,n   Coates, Alan S ^r,s   Goldhirsch, Aron ^e,t  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b Protocols Working Group   (Switzerland)

^c Statistical Center   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f INSTITUTE OF ONCOLOGY   (Slovenia)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h Anatomica Patologica   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j W Aust Ctr for Pathol Med Res   (Australia)

^k Intl Breast Cancer Study Group   (United Kingdom)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m IBCSG Coordinating Center   (Switzerland)

ⁿ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^o Oncologia Medica   (Italy)

^p SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^q ROYAL MELBOURNE HOSPITAL   (Australia)

^r CANCER COUNCIL AUSTRALIA   (Australia)

^s UNIVERSITY OF SYDNEY   (Australia)

^t Oncol Inst of S Switzerland   (Switzerland)

more..

Author keywords

Adjuvant chemotherapy; Breast carcinoma; HER 2 neu; Ki 67; p27; Predictive factors

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PREDNISONE; PROGESTERONE RECEPTOR; PROTEIN P27; TAMOXIFEN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE NEU; PERIOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CHEMOTHERAPY, ADJUVANT; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0037377745     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11224     Document Type: Article

References (28)

1. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat. 1998;52:305-319.
2. Fero ML, Randel E, Gurley KE, et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998;396:177-180.
3. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 [see comments]. Science. 1995;269:682-685.
4. Cariou S, Catzavelos C, Slingerland JM. Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Breast Cancer Res Treat. 1998;52:29-41.
5. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27/Kip 1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227-230.
6. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27/Kip1 and cyclin E, alone or in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222-225.
7. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997;57:1259-1263.
8. Gillett CE, Smith P, Peters G, et al. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol. 1999;187:200-206.
9. Leong AC, Hanby AM, Potts HW, et al. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer. 2000;89:26-31.
10. Barbareschi M, van Tinteren H, Mauri FA, et al. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer. 2000;89:236-241.
11. Wu J, Shen ZZ, Lu JS, et al. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer. 1999;79: 1572-1578.
12. The Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med. 1988;319:677-683.
13. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989;320:491-496.
14. Goldhirsch A, Gelber RD, Castiglione M, et al. Present and future projects of the International Breast Cancer Study Group. Cancer. 1994;74:1139-1149.
15. Pinder SE, Murray S, Ellis IO, et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer. 1998;83:1529-1539.
16. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:1049-1056.
17. Pestalozzi BC, Peterson HF, Gelber RD, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997;15:1923-1931.
18. Viale G, Pellegrini C, Mazzarol G, et al. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. J Pathol. 1999;187:302-307.
19. Cox D. Analysis of binary data. London: Methuen and Company, 1970.
20. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80-83.
21. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:181-220.
22. Kaplan EL, Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Chappuis PO, Kapusta L, Begin LR, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000;18:4045-4052.
24. Newman L, Xia W, Yang HY, et al. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinogenis. 2001;30:169-175.
25. Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000;20:3210-3223.
26. Lenferink AE, Simpson JF, Shawver LK, et al. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci USA. 2000;97:9609-9614.
27. Neville AM, Bettelheim R, Gelber RD, et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:696-705.
28. Colleoni M, Gelber S, Coates AS, et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol. 2001;21:4141-4149.